We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Boehringer Ingelheim and the BioMed X Innovation Center are using crowdsourcing to assemble a research team to identify new approaches to treat chronic obstructive pulmonary disease. Read More
Pfizer’s oral Xeljanz sent more patients suffering from moderate to severe ulcerative colitis into remission, meeting primary endpoints in two Phase 3 clinical trials, the company reported Monday. Read More
The FDA has awarded research grants totaling more than $19 million to boost the development of products to treat 17 different rare diseases, many of which have little or no available treatment options. Read More
The U.S. government is awarding $62 million to Regeneron Pharmaceuticals and Inovio Pharmaceuticals to support their ongoing development of novel Ebola virus treatments. Read More
Antibiotics developer Cempra said Friday the FDA granted a qualified infectious disease product designation for its investigational candidate Taksta to treat acute bacterial skin and skin structure infections. Read More
A trial of a cervical cancer treatment by New Jersey biotech company Advaxis demonstrated it could extend life further than existing treatments in women with persistent, advanced forms of the disease. Read More
HHS will collaborate with biopharmaceutical giant AstraZeneca on an antibiotic initiative as part of a biodefense preparedness plan for dealing with public health threats. Read More
California-based biopharmaceutical companies Amgen and Xencor entered into a research and license agreement that could be worth as much as $1.7 billion to develop and commercialize therapeutics focused on cancer immunotherapy and inflammation. Read More